Life ScienceCompany
Catalyst Biosciences - Rare Disease Pipeline in Hematology Ownership
Who owns Catalyst Biosciences - Rare Disease Pipeline in Hematology?
Catalyst Biosciences - Rare Disease Pipeline in Hematology is owned by GC Biopharma. It was acquired on February 28, 2023.
Catalyst Biosciences - Rare Disease Pipeline in Hematology Business Overview
Where is Catalyst Biosciences - Rare Disease Pipeline in Hematology headquartered?
Catalyst Biosciences - Rare Disease Pipeline in Hematology is headquartered in San Francisco, California.
What sector is Catalyst Biosciences - Rare Disease Pipeline in Hematology in?
Catalyst Biosciences - Rare Disease Pipeline in Hematology is a life science company.
Life Science M&A Summary in 2023
Out of 60 sectors in the Mergr database, life science ranked 9 in number of deals in 2023. The largest life science acquisition in 2023 was Seagen - which was acquired by Pfizer for $43.0B.
Join Mergr to view all 196 acquisitions of life science companies in 2023, including 22 acquisitions by private equity firms, and 174 by strategics.